ABSTRACT
A hepatotoxicity can be observed at the use of different groups of antitumoral drugs. Cytotoxicity drugs have a leading place in relation to incidence and severity of liver damage. During chemotherapy the development of hepatotoxicity is caused by thedamage of the liver parenchymal cells with fatty degeneration, necrosis of the liver tissue, and cholestasis. The study of the mechanisms of development, clinical course and laboratory manifestations of hepatotoxicity of chemotherapy will lead to its prevention or reduction, which will improve the immediate and long-term results of treatment of patients with cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/toxicity , Chemical and Drug Induced Liver Injury/etiology , Cytostatic Agents/toxicity , Liver/drug effects , Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemical and Drug Induced Liver Injury/pathology , Cytostatic Agents/therapeutic use , Humans , Liver/pathologyABSTRACT
In modern oncology chemotherapy (CT), along with the surgical technique and radiotherapy is a leader in the treatment of cancer patients. More than 60% of patients receiving chemotherapy at different stages of treatment. Recently, modern chemotherapy has become more urgent personal approach to the choice of drugs and their doses, aimed at reducing the toxicity of chemotherapy. Complications of chemotherapy significantly degrade the effectiveness of the treatment of patients with malignant tumors, because they require lower doses of anticancer drug, or lengthening the intervals between cycles of chemotherapy, which affects treatment outcomes and quality of life. This paper presents a literature review of toxic effects of cytostatic drugs on the gastrointestinal tract.
Subject(s)
Antineoplastic Agents/adverse effects , Cytostatic Agents/adverse effects , Gastrointestinal Tract/drug effects , Neoplasms/drug therapy , Adrenal Cortex Hormones/pharmacology , Adrenal Cortex Hormones/therapeutic use , Gastrointestinal Tract/pathology , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Mouth Mucosa/drug effects , Mouth Mucosa/pathology , Nausea/prevention & control , Neoplasms/pathology , Serotonin Antagonists/pharmacology , Serotonin Antagonists/therapeutic use , Treatment Outcome , Vomiting/prevention & controlABSTRACT
Treatment of patients with metastatic breast cancer is one of the most difficult problems of clinical oncology. Chemotherapy is one of the main methods of treatment of patients with metastatic breast cancer. Long experience of the world's cancer centers, advances in clinical oncology recent decades, the synthesis of anticancer drugs with new mechanisms of action have led to progress in the treatment of disseminated breast cancer. However, as shown by recent studies, the improvement of chemotherapy is not associated with reduced mortality from this disease. This paper presents the effectiveness of anticancer drugs and their combinations in the treatment of patients with metastatic breast cancer. Compliance with which, as it seems to us to produce superior results in treating this disease.
Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms , Combined Modality Therapy/methods , Neoplasm Metastasis , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Drug Administration Routes , Drug Administration Schedule , Female , Humans , Survival Rate , Treatment OutcomeABSTRACT
The results of Poliplatillen clinical application in 108 patients with advanced pancreatic cancer were analyzed. The use of Poliplatillen in adjuvant regimen improves the long-term results of treatment. The mean survival time was increased on 2.9 months, which was statistically significant, mediana survival was increased on 1.5 months, 10% of patients alived 20 months, 20%--16 months. Survival of patients of control group did not exceed 12 months.
